LUNG-RESIST_en

6 Dec 2021 | Unclassified

LUNG-RESIST Lung cancer is the major cause of cancer-related death in France and worldwide. In the past few years, patients with specific genetic alterations such as mutations in the EGFR gene (about 15% of lung adenocarcinomas, 45% in non-smokers), have benefited...

MELANICa_en

6 Dec 2021 | Unclassified

MELANICa Immunotherapies have revolutionised the therapeutic management of melanoma by increasing the immune response against this dreaded skin cancer. However, not all patients respond to immunotherapies and some relapse within two years following treatment...

Comm’in BCen

1 Dec 2021 | Unclassified

Comm’in BC The role of the tumor immune microenvironment has been poorly investigated in breast cancer (BC) and particularly in estrogen receptor positive (ER+) low-grade luminal A and high-grade luminal B subsets. Tissue-resident memory cells (TRM), a subset of...

LMSTARen

30 Nov 2021 | Unclassified

LMSTAR Leiomyosarcomas (LMS) are among the most common sarcomas and their prognosis is still poor. No effective systemic treatment has been identified so far and surgery remains the mainstay of management. Their oncogenesis remains poorly understood. To decipher this...

GAMERen

29 Nov 2021 | Unclassified

GAMER Myeloma is a bone marrow cancer that accounts for just over 10% of haematological cancers, with a median age at diagnosis of 70 years. Some so-called high genetic risk patients have a particularly poor prognosis. We have recently shown that early relapse of the...

Pin It on Pinterest